The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
Dean Erhardt
Advertisement
Articles by Dean Erhardt
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=350&fit=crop&auto=format)
A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.
Advertisement
Latest Updated Articles
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=300&fit=crop&auto=format)
Proposed Rule to Eliminate Pharmaceutical Rebates Raises Challenging QuestionsPublished: May 22nd 2019 | Updated:
Proposed Rebates Rule Raises Tough QuestionsPublished: July 16th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
Bob Mauch: Strengthening the Chain
3
Pharmaceutical Executive Daily: Novo Nordisk's Board Shake-Up
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
